Elizabeth Thompson Biography and Net Worth

EVP Head of Research and Development of ACADIA Pharmaceuticals

Dr. Elizabeth H.Z. Thompson is Acadia’s Executive Vice President, Head of Research and Development where she leads the R&D organization in the development of new products in rare and central nervous system disorders and other opportunities to expand our pipeline of medicines. She joined Acadia in April 2024.

Dr. Thompson served most recently as Executive Vice President, Research and Development (Rare Disease) at Amgen following its acquisition of Horizon Therapeutics plc. At Horizon, Dr. Thompson served in roles of increasing responsibility including as Executive Vice President, Research and Development at the time of Horizon’s acquisition. Prior to joining Horizon, she was with AbbVie as Group Scientific Director, Clinical Development and, before that, Senior Scientific Director, Clinical Development. Before AbbVie, Dr. Thompson held roles at Raptor, InterMune and Amgen in a career spanning clinical development, business development and medical communications.

Dr. Thompson received a Bachelor of Science degree in Chemistry from Harvey Mudd College and a Doctorate in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute.

How do I contact Elizabeth H.Z. Thompson?: The corporate mailing address for Dr. Thompson and other ACADIA Pharmaceuticals executives is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. ACADIA Pharmaceuticals can also be reached via phone at (858) 558-2871 and via email at [email protected]. Learn More on Elizabeth H.Z. Thompson's contact information.
Has Elizabeth H.Z. Thompson been buying or selling shares of ACADIA Pharmaceuticals?: Elizabeth H.Z. Thompson has not been actively trading shares of ACADIA Pharmaceuticals over the course of the past ninety days. Learn More on Elizabeth H.Z. Thompson's trading history.
Who are ACADIA Pharmaceuticals' active insiders?: ACADIA Pharmaceuticals' insider roster includes Laura Brege (Director), James Daly (Director), Stephen Davis (CEO), Elizabeth Garofalo (Director), James Kihara (Insider), Austin Kim (EVP), Jennifer Rhodes (Chief Legal Officer and Secretary), Elena Ridloff (CFO), Mark Schneyer (CFO), Srdjan Stankovic (President), Brendan Teehan (COO), and Elizabeth Thompson (EVP Head of Research and Development). Learn More on ACADIA Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ACADIA Pharmaceuticals?: During the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 108,930 shares worth more than $2,587,182.98. The most recent insider tranaction occured on July, 30th when EVP Elizabeth H.Z. Thompson sold 16,558 shares worth more than $432,660.54. Insiders at ACADIA Pharmaceuticals own 26.2% of the company. Learn More about insider trades at ACADIA Pharmaceuticals.
Information on this page was last updated on 7/30/2026.

Elizabeth H.Z. Thompson Insider Trading History at ACADIA Pharmaceuticals

Elizabeth H.Z. Thompson Buying and Selling Activity at ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $25.52

$25.43

$26.11

50 Day Range

MA: $23.74

$20.89

$26.55

2 Week Range

Now: $25.52

$19.69

$28.35

Volume

684,905 shs

Average Volume

1,644,418 shs

Market Capitalization

$4.37 billion

P/E Ratio

11.59

Dividend Yield

N/A

Beta

0.81